menu search

Marker therapeutics stock gains on fda orphan drug tag for second multitaa-cell therapy for pancreatic cancer

The FDA has granted Orphan Drug Designation to Marker Therapeutics Inc's (NASDAQ: MRKR) MT-601, a multi-tumor-associated antigen (MultiTAA)-specif...

January 20, 2022, 6:38 am

Marker therapeutics stock gains on fda orphan drug tag for second multitaa-cell therapy for pancreatic cancer

The FDA has granted Orphan Drug Designation to Marker Therapeutics Inc's (NASDAQ: MRKR) MT-601, a multi-tumor-associated antigen (MultiTAA)-specif...

January 20, 2022, 6:38 am

Marker therapeutics stock gains on fda orphan drug tag for second multitaa-cell therapy for pancreatic cancer

The FDA has granted Orphan Drug Designation to Marker Therapeutics Inc's (NASDAQ: MRKR) MT-601, a multi-tumor-associated antigen (MultiTAA)-specif...

January 20, 2022, 6:38 am

In8bio stock jumps after an update from leukemia trial

IN8bio Inc (NASDAQ: INAB) has provided an update on the Phase 1 clinical trial of INB-100, a donor-derived gamma-delta T cell therapy for leukemia ...

December 16, 2021, 1:06 pm

In8bio stock jumps after an update from leukemia trial

IN8bio Inc (NASDAQ: INAB) has provided an update on the Phase 1 clinical trial of INB-100, a donor-derived gamma-delta T cell therapy for leukemia ...

December 16, 2021, 1:06 pm

In8bio stock jumps after an update from leukemia trial

IN8bio Inc (NASDAQ: INAB) has provided an update on the Phase 1 clinical trial of INB-100, a donor-derived gamma-delta T cell therapy for leukemia ...

December 16, 2021, 1:06 pm

Fda advisory committee recommends use of investigational drug maribavir (tak-620) to treat post-transplant recipients with cytomegalovirus (cmv) infection and disease refractory to treatment with or w

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the U.S. Fo...

October 7, 2021, 6:15 pm

Fda advisory committee recommends use of investigational drug maribavir (tak-620) to treat post-transplant recipients with cytomegalovirus (cmv) infection and disease refractory to treatment with or w

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the U.S. Fo...

October 7, 2021, 6:15 pm

Fda advisory committee recommends use of investigational drug maribavir (tak-620) to treat post-transplant recipients with cytomegalovirus (cmv) infection and disease refractory to treatment with or w

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the U.S. Fo...

October 7, 2021, 6:15 pm

Fda advisory committee recommends use of investigational drug maribavir (tak-620) to treat post-transplant recipients with cytomegalovirus (cmv) infection and disease refractory to treatment with or w

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the U.S. Fo...

October 7, 2021, 6:15 pm

Fda advisory committee recommends use of investigational drug maribavir (tak-620) to treat post-transplant recipients with cytomegalovirus (cmv) infection and disease refractory to treatment with or w

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the U.S. Fo...

October 7, 2021, 6:15 pm

Fda advisory committee recommends use of investigational drug maribavir (tak-620) to treat post-transplant recipients with cytomegalovirus (cmv) infection and disease refractory to treatment with or w

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the U.S. Fo...

October 7, 2021, 6:15 pm

Eledon pharmaceuticals announces presentation on at-1501 at the virtual 2021 northeast amyotrophic lateral sclerosis consortium

IRVINE, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical compa...

October 7, 2021, 7:51 am

Eledon pharmaceuticals announces presentation on at-1501 at the virtual 2021 northeast amyotrophic lateral sclerosis consortium

IRVINE, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical compa...

October 7, 2021, 7:51 am

Eledon pharmaceuticals announces presentation on at-1501 at the virtual 2021 northeast amyotrophic lateral sclerosis consortium

IRVINE, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical compa...

October 7, 2021, 7:51 am

Natera announces completion of the largest prospective validation study of a commercial cell-free dna test in lung transplantation

AUSTIN, Texas, Oct. 6, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in improving patient outcomes through genetic and cell-free DNA (cf...

October 6, 2021, 8:33 am

Natera announces completion of the largest prospective validation study of a commercial cell-free dna test in lung transplantation

AUSTIN, Texas, Oct. 6, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in improving patient outcomes through genetic and cell-free DNA (cf...

October 6, 2021, 8:33 am

Natera announces completion of the largest prospective validation study of a commercial cell-free dna test in lung transplantation

AUSTIN, Texas, Oct. 6, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in improving patient outcomes through genetic and cell-free DNA (cf...

October 6, 2021, 8:33 am


Search within

Pages Search Results: